^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET amplification

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. (PubMed, JCO Precis Oncol)
    Amplification of wild-type RET represents a novel, targetable molecular subset of cancer.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET rearrangement • RET amplification • RET wild-type
    |
    Retevmo (selpercatinib)
    over1year
    Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials (IASLC-WCLC 2023)
    In this study, we report preliminary results of potential molecular mechanisms underlying disease progression in patients treated with neoadjuvant nivolumab plus chemotherapy using plasma samples from NADIM and NADIM II cohorts. A total of 10 plasma samples collected upon disease progression from patients included in NADIM or NADIM II trials were analyzed... Acquisition of somatic-copy number alterations in RET, EGFR and FGFR was found in the plasma samples collected upon disease progression in patients treated with neoadjuvant chemoimmunotherapy (NADIM I and II cohorts) which may have important implications for subsequent treatment selection.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RET (Ret Proto-Oncogene) • FGFR3 (Fibroblast growth factor receptor 3) • STK11 (Serine/threonine kinase 11) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • RNF43 (Ring Finger Protein 43) • SETBP1 (SET Binding Protein 1) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)
    |
    TP53 mutation • EGFR amplification • STK11 mutation • DNMT3A mutation • TET2 mutation • CBL mutation • RNF43 mutation • FGFR3 amplification • RET amplification
    |
    TruSight Oncology 500 Assay • Oncomine Tumor Mutation Load Assay
    |
    Opdivo (nivolumab)